Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8974485 | 0.86 | PTGS2 (0.71) | PTGS2PTGS1 | |
| SCHEMBL214628 | 0.85 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL8974084 | 0.84 | PTGS2 (0.53) | PTGS2PTGS1 | |
| SCHEMBL8974475 | 0.84 | PTGS2 (0.53) | PTGS2PTGS1 | |
| SCHEMBL8974303 | 0.84 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL213199 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5698515 | 0.83 | PTGS2 (0.52) | PTGS2PTGS1 | |
| SCHEMBL8974669 | 0.83 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL9117072 | 0.82 | PTGS2 (0.66) | PTGS2PTGS1 | |
| SCHEMBL8974299 | 0.82 | PTGS2 (0.66) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2023914-A2 | METHODS OF TREATING A NEUROLOGICAL DISORDER WITH CREATINE MONOHYDRATE | Avicena Group, Inc. (US) | 2009-02-18 | — | — | EP | claimed |
| EP-2023718-A2 | CREATINE-LIGAND COMPOUNDS AND METHODS OF USE THEREOF | Avicena Group, Inc. (US) | 2009-02-18 | — | — | EP | claimed |
| EP-1479385-B1 | Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | SEARLE LLC (US) | 2008-07-02 | — | — | EP | claimed |
| WO-2007133731-A2 | CREATINE-LIGAND COMPOUNDS AND METHODS OF USE THEREOF | AVICENA GROUP, INC. (US) | 2007-11-22 | — | — | WO | claimed |
| WO-2007133673-A2 | METHODS OF TREATING A NEUROLOGICAL DISORDER WITH CREATINE MONOHYDRATE | AVICENA GROUP, INC. (US) | 2007-11-22 | — | — | WO | claimed |
| US-20060093687-A1 | Combinations of a vanilloid antagonist and an nsaid for the treatment of pain | BOUNTRA CHARANJIT | 2006-05-04 | — | — | US | claimed |
| EP-0843549-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4 HYDROLASE INHIBITOR | SEARLE & CO (US) | 2006-04-12 | — | — | EP | claimed |
| EP-0833622-B8 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-10-12 | — | — | EP | claimed |
| EP-1572237-A1 | COMBINATIONS OF VANILLOID ANTAGONIST AND NSAID FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2005-09-14 | — | — | EP | claimed |
| EP-0833622-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-08-10 | — | — | EP | claimed |
| WO-1999059635-A1 | USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION | MERCK SHARP & DOHME LIMITED (GB) | 1999-11-25 | — | — | WO | claimed |
| WO-1998050075-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| EP-0843549-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4? HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0833622-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| EP-0833664-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B 4? RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1996041645-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996041625-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996041626-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1995030656-A1 | SUBSTITUTED CYCLOPENTADIENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1995-11-16 | — | — | WO | claimed |
| US-5418254-A | Side effect reduction | G. D. SEARLE & CO. (US) | 1995-05-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060093687-A1 | Combinations of a vanilloid antagonist and an nsaid for the treatment of pain | TRPV1, TRPV2, TRPV3 | PTGS2 129/4885PTGS1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.